06 sep: Europa/Luk: ECB åbnede for sluserne
07 sep: USA/aktier: Wall Street fejrede ECB-plan
06-09-2012 18:45:00

Weak August Sales, Tricare Decision Weigh on Walgreen

Relateret indhold
Relateret debat
13 jul - 
naturligvis. Sygemennsker er lækre at udnytte- de er pa..
13 jul - 
10 Hospitals With 340B Contract Pharmacy Mega-Networks ..

--Shares fall despite broader market rally as investors digest disappointing sales news and Tricare's network decision

--Tricare health plan won't let its beneficiaries who get drug coverage through Express Scripts resume getting prescriptions filled at Walgreen

--Walgreen had previously indicated Tricare represented about 15 million prescriptions in 2011

Shares of Walgreen Co. (WAG) are under pressure Thursday as the broader market rallies, with investors digesting news of weak sales in August and a decision by the U.S. Department of Defense's Tricare health plan to continue to exclude the pharmacy chain from its provider network.

Earlier Thursday, Walgreen said the company's same-store sales fell a bigger-than-expected 8.2% during August, as the pharmacy giant continued to suffer from generic-drug introductions and its dispute with Express Scripts Holding Co. (ESRX). Analysts surveyed by Thomson Reuters expected a decline of 7.3%.

Though August's same-store sales and total sales for the fiscal fourth quarter were disappointing, analysts and investors seemed to focus more on Tricare's announcement Wednesday evening, when it said it wouldn't let its nearly 10 million beneficiaries who get drug coverage through Express Scripts resume getting prescriptions filled at Walgreen outlets.

Walgreen had previously indicated Tricare represented about 15 million prescriptions in 2011, making up about 17% of the 88 million prescriptions filled at Walgreen pharmacies by Express Scripts members last year.

The decision is a setback for Walgreen as the drugstore chain tries to gain customers it lost starting Jan. 1, when it broke ties with Express Scripts. Walgreen and Express Scripts recently mended fences, but entities that hire Express Scripts to manage pharmacy benefits will have to specifically add Walgreen drugstores to their network before members can get prescriptions covered there.

Tricare's decision highlights the heightened interest among employers and health plans to opt for so-called "narrow networks," as clients look for savings by aiming to balance between drugstore options and prices for health-plan sponsors.

Though Walgreen has contended that clients aren't interested in narrow networks, J.P. Morgan analyst Lisa Gill in a research note said the current selling season for pharmacy-benefit managers showed more interest in the savings narrow networks can drive.

"We believe the Tricare decision is an incremental positive for CVS, as it should help lead to higher long-term prescription-retention rates," Ms. Gill said.

Shares of CVS Caremark Corp. (CVS) were up 1.9% to $46.40, better than the broader market's rally, while Walgreen's stock fell 2.5% to $34.98.

Jefferies analyst Brian Tanquilut said that while some Express Scripts clients, such as managed-care provider WellPoint Inc. (WLP), have adopted a broader pharmacy network that includes Walgreen beginning Sept. 15, Tricare's move bolsters Express Scripts's push for narrower networks. By restricting access to more-expensive retail pharmacies, Mr. Tanquilut said clients could reduce pharmacy costs while the company can generate better margins.

In August, Walgreen saw its sales fall 4.5% from the year-ago month to $5.85 billion.

Total comparable-store front-end sales decreased 0.6%, while prescriptions filled at comparable stores decreased 6.8% in August. Walgreen said the negative impact on comparable-store prescriptions filled due to not being part of the Express Scripts pharmacy network was 10.7 percentage points in August. Prescriptions processed by Express Scripts comprised about 13% of Walgreen prescriptions in August 2011.

Walgreen said the effect of generic-drug introductions in the last 12 months hurt total comparable sales by 5.1 percentage points. The industry's same-store sales have been hurt by rising demand for new generic drugs hitting the market, as they carry lower prices than branded products.

Total sales for the fiscal fourth quarter fell 4.9% to $17.08 billion, below analysts' expectations of $17.21 billion. Comparable-store sales for the fourth quarter decreased 8.7%, while front-end comparable-store sales for the quarter decreased 1.3%. Prescriptions filled at comparable stores decreased 8% in the fourth quarter, and comparable-pharmacy sales decreased 13%.

--Jon Kamp and Saabira Chaudhuri contributed to this article.

Write to John Kell at john.kell@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

September 06, 2012 12:45 ET (16:45 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Nordea/CEO: Vigtigt med grundig analyse om hovedkvarter

20-07-2017 12:36:25
Det bliver til september, at Nordea afslører, om banken har tænkt sig at flytte sit hovedkvarter.Det fremgik af bankens regnskab torsdag morgen og blev uddybet senere over for Ritzau Finans.Udskydelsen skyldes dels nye initiativer, som banken skriver i regnskabet, og dels vigtigheden af at have yderligere tid til analyserne.- Vi tager beslutningen for de næste ti år. Vi har så småt fakta på plads,..

Aktier/middag: Storbankerne falder til bunds i C20 efter regnskaber

20-07-2017 11:33:47
Nordea og Danske Bank har ikke formået at stille investorerne tilfredse med deres respektive halvårsregnskaber torsdag, og derfor er de to aktier faldet til bunds og bidrager til at holde det danske eliteindeks tilbage.C20 Cap-indekset falder 0,1 pct. til 1176,18, mens der ellers er relativt godt humør på de europæiske børser. Risikoappetitten tager til efter fremgang på børserne i både Asien og U..

Danske/Jyske: Positive nedskrivninger lyser op i pænt regnskab - NY

20-07-2017 08:23:27
Det er især en sund udvikling i kundernes økonomi, der er et væsentligt element i et ganske fornuftigt regnskab fra Danske Bank.Der var dog på forhånd ventet pæne tal fra Danmarks største bank, og derfor bør aktien ikke rokke sig voldsomt i torsdagens handel på aktiemarkedet.Det vurderer aktieanalytiker Thomas Eskildsen fra Jyske Bank.- Det er et fint regnskab, og banken er inde i en ganske stabil..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Pandora-aktien tager stort hop efter rygstød fra investeringsbank - NY
2
Aktier/middag: Storbankerne falder til bunds i C20 efter regnskaber
3
Torsdagens aktier: Pandora funklede mens Nordea og Danske skuffede
4
Nordea Q2: Skuffer tungt og udskyder beslutning om hovedkvarter
5
Danske Bank Q2: Sundere problemkunder sikrede pænt plus i kvartalet

Relaterede aktiekurser

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
20. juli 2017 22:38:41
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170720.2 - EUROWEB2 - 2017-07-20 22:38:41 - 2017-07-20 22:38:41 - 1 - Website: OKAY